Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of afatinib and necitumumab and to
see how well they work in treating patients with EGFR mutation positive non-small cell lung
cancer that has spread to other places in the body. Afatinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
necitumumab, may interfere with the ability of tumor cells to grow and spread. Giving
afatinib and necitumumab may work better in treating patients with EGFR mutation positive
non-small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network